ArticleJournal of translational medicine2021

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab.

Rosaria De Filippi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.